Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 567 clinical trials
featured
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

refractory multiple myeloma who have received at least 3 but not more than 5 prior lines of multiple myeloma therapy.  

refractory multiple myeloma
daratumumab
  • 71 views
  • 28 May, 2020
  • 28 locations
featured
EAY131: Molecular Analysis for Therapy Choice (MATCH)

EAY131: Molecular Analysis for Therapy Choice (MATCH)

multiple myeloma
solid tumors
lymphoma
  • 98 views
  • 24 Nov, 2020
  • 1 location
featured
A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy

A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High

  • 154 views
  • 25 Mar, 2021
  • 1 location
Multi Centre Trial of DSMM for Newly Diagnosed Multiple Myeloma up to 60 Years

The study is evaluating whether risk-stratification by the means of a chromosomal aberration provides a tool to discriminate between standard and high risk. Risk-adapted therapy is based on allogeneic stem-cell transplantation for high-risk subjects instead of a second autograft in patients with deletion of chromosome 13 who have an HLA-identical …

autograft
cell transplantation
  • 30 views
  • 07 Nov, 2020
  • 15 locations
Carfilzomib Thalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

All patients with multiple myeloma (MM) are destined to relapse even with the best available approved agents. Median OS from diagnosis in the current era is reported at 5.4 years. Given that

  • 22 views
  • 21 Jan, 2021
  • 1 location
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Primary Objectives: Part 1 (dose finding, experimental substudies): To determine or confirm the recommended dose of novel agents when combined with isatuximab with or without dexamethasone in participants with RRMM. Part 2 (expansion, experimental substudies): To demonstrate the clinical benefit of novel agents combined with isatuximab with or without dexamethasone …

  • 0 views
  • 14 Jun, 2021
  • 9 locations
Pomalidomide-Cyclophosphamide-Dexamethasone (PCD) Versus Pomalidomide-Dexamethasone (PD) in Relapse or Refractory Myeloma

Myeloma patients who relapse after prior treatment with bortezomib and lenalidomide have survival of less than 1 year. Recently, a randomized study of Pomalidomide and dexamethasone conducted in

induction therapy
maintenance therapy
cancer
vasectomy
cyclophosphamide
  • 33 views
  • 21 Jan, 2021
  • 3 locations
Elotuzumab in Combination With Carfilzomib Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

should result in an even higher rate of deep (negative for MRD in conjunction with at least very good partial response [VGPR] as defined by the International Myeloma Working Group [IMWG]) with these

  • 8 views
  • 03 Mar, 2021
  • 58 locations
Study of Early Relapsed Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

A Study Evaluating Treatment of Multiple Myeloma with Carfilzomib in Combination with Pomalidomide and Dexamethasone

  • 0 views
  • 13 Jun, 2021
  • 37 locations
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

combination with lenalidomide and dexamethasone (KRd 27 mg/m2) in subjects with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy.

  • 18 views
  • 13 Jun, 2021
  • 221 locations